A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …

Abstract The recently published International Consensus Classification (ICC) of myeloid
neoplasms summarized the results of an in-depth effort by pathologists, oncologists, and …

Background Polycythemia vera is a chronic myeloproliferative neoplasm characterized by
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/
hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV …

We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in
polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled …

Background Whether phlebotomy alone can adequately maintain target hematocrit in
patients with low-risk polycythemia vera (PV) remains elusive. Methods In a phase 2 open …

Disease Overview JAK2 unmutated or non‐polycythemia vera (PV) erythrocytosis
encompasses a heterogenous spectrum of hereditary and acquired entities. Diagnosis …

A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was
presented at the ISTH congress in 2021. We summarize here the main points of the lecture …

Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …

Hepcidin mimetics in polycythemia vera: resolving the irony... : Current Opinion in Hematology
Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis …